Clincosm LogoSign in Get a demo

Can Epidermal Growth Factor Receptor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis ?

Sponsor
Taipei Veterans General Hospital, Taiwan (Other)
Overall Status
Completed
CT.gov ID
NCT02740894
Collaborator
(none)
100
Enrollment
2
Duration (Months)

Study Details

Study Description

Brief Summary

Not significantly increased survival in T/T

Condition or Disease Intervention/Treatment Phase

Study Design

Study Type:
Observational
Actual Enrollment :
100 participants
Observational Model:
Case-Only
Time Perspective:
Retrospective
Official Title:
Can Epidermal Growth Factor Receptor - Tyrosine Kinase Inhibitor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis of the Thoracic and Lumbar Spine?- A Retrospective Comparison With Platinum-based Chemotherapy
Study Start Date :
Feb 1, 2016
Actual Primary Completion Date :
Apr 1, 2016
Actual Study Completion Date :
Apr 1, 2016

Arms and Interventions

Arm Intervention/Treatment
targeted therapy

according to national healthy policy, targeted therapy is the optional therapy

Drug: Gefitinib
Other Names:
  • Targeted therapy

    		•
    traditional chemotherapy

    according to national healthy policy, chemotherapy is the first line treatment.

    Drug: Gefitinib
    Other Names:
  • Targeted therapy

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Survival and neurologic outcome of 60 participants receiving targeted therapy for nonsmall cell lung cancer with spinal metastaasis. Neurological outcome by Frankel grading and ambulation status. [postoperation to mortality, up to 2 year]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • NSCLC with spinal metastasis
    Exclusion Criteria:
    • brain metastasis and expected survival < 3 months

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Taipei Veterans General Hospital, Taiwan

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    vghtpe user, ST Wang, Chief of spinal surgery. Taipei Veterans General Hospital, Taiwan, Taipei Veterans General Hospital, Taiwan
    ClinicalTrials.gov Identifier:
    NCT02740894
    Other Study ID Numbers:
    • 2016-02-006CC
    First Posted:
    Apr 15, 2016
    Last Update Posted:
    Apr 15, 2016
    Last Verified:
    Apr 1, 2016
    Additional relevant MeSH terms:
    Lung Neoplasms
    Carcinoma, Non-Small-Cell Lung
    Neoplasm Metastasis
    Gefitinib

    Study Results

    No Results Posted as of Apr 15, 2016